These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 1458766)
21. Adverse drug reactions: a review for healthcare practitioners. Young LR; Wurtzbacher JD; Blankenship CS Am J Manag Care; 1997 Dec; 3(12):1884-906; quiz 1909-10. PubMed ID: 10178476 [No Abstract] [Full Text] [Related]
22. CONTROL OF DRUG TOXICITY IN THE UNITED STATES OF AMERICA. WESTON JK; WESTON K Practitioner; 1965 Jan; 194():16-21. PubMed ID: 14259685 [No Abstract] [Full Text] [Related]
23. [FOODS-DRUGS-POISONS. ELEMENTS OF DEFINITION]. TREMOLIERES J J Med Chir Prat; 1964 Oct; 135():339-47. PubMed ID: 14225293 [No Abstract] [Full Text] [Related]
24. Inadequate and delayed characterization of cutaneous reactions for US Food and Drug Administration-approved oncologic drugs from 2011-2020 leading to medication discontinuation. Yang JJ; So N; Maloney NJ; Arzeno J; Clifton KK; Bach DQ J Am Acad Dermatol; 2021 Nov; 85(5):1351-1352. PubMed ID: 33236990 [No Abstract] [Full Text] [Related]
25. Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project. de Bie S; Ferrajolo C; Straus SM; Verhamme KM; Bonhoeffer J; Wong IC; Sturkenboom MC; PLoS One; 2015; 10(6):e0130399. PubMed ID: 26090678 [TBL] [Abstract][Full Text] [Related]
26. Review of embryo-fetal developmental toxicity studies performed for pharmaceuticals approved by FDA in 2016 and 2017. Barrow P Reprod Toxicol; 2018 Sep; 80():117-125. PubMed ID: 29660390 [TBL] [Abstract][Full Text] [Related]
27. REPORTING OF ADVERSE REACTIONS TO DRUGS. WINTROBE MM Ann Intern Med; 1965 Jan; 62():170-4. PubMed ID: 14258346 [No Abstract] [Full Text] [Related]
28. FDA holds public meeting on nanotechnology. Traynor K Am J Health Syst Pharm; 2006 Nov; 63(22):2175-7. PubMed ID: 17090732 [No Abstract] [Full Text] [Related]
29. U.S. Food and Drug Administration. "Evaluation Criteria" for Difficult to Compound Drugs. Allen LV Int J Pharm Compd; 2015; 19(6):487-8. PubMed ID: 26891563 [TBL] [Abstract][Full Text] [Related]
30. Experience in monitoring drug reactions in outpatients. The Kaiser-Permanente Drug Monitoring System. Friedman GD; Collen MF; Harris LE; Van Brunt EE; Davis LS JAMA; 1971 Aug; 217(5):567-72. PubMed ID: 5109088 [No Abstract] [Full Text] [Related]
31. Drugs on the market. JAMA; 1970 Feb; 211(7):1177. PubMed ID: 5466970 [No Abstract] [Full Text] [Related]
32. Safer drugs for children. Environ Health Perspect; 1999 Jun; 107(6):A296. PubMed ID: 10515711 [No Abstract] [Full Text] [Related]
33. New Drugs Approved in 2020. Ebied AM; Elmariah H; Cooper-DeHoff RM Am J Med; 2021 Sep; 134(9):1096-1100. PubMed ID: 33939997 [TBL] [Abstract][Full Text] [Related]
34. Pharmaceutical drugs-the good and the not so good: together, we can make it better. Campbell AW Altern Ther Health Med; 2014; 20(1):9-11. PubMed ID: 24445351 [No Abstract] [Full Text] [Related]
35. Drug safety: Pregnancy rating classifications and controversies. Wilmer E; Chai S; Kroumpouzos G Clin Dermatol; 2016; 34(3):401-9. PubMed ID: 27265079 [TBL] [Abstract][Full Text] [Related]
36. New drugs: the tortuous road to approval. Visscher MB Science; 1967 Apr; 156(3773):313. PubMed ID: 4887262 [No Abstract] [Full Text] [Related]
37. Plan BTC: the case for a third class of drugs in the United States. Healey D Food Drug Law J; 2008; 63(1):375-89. PubMed ID: 18561465 [No Abstract] [Full Text] [Related]
38. FDA's classification of new drugs. Schneiweiss F N Engl J Med; 1980 Jun; 302(24):1368-9. PubMed ID: 7374693 [No Abstract] [Full Text] [Related]